Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency

Atherosclerosis

Volumn 228, Issue 2, 2013, Pages 380-385

  Jänis, Minna T ^a   Tarasov, Kirill ^a   Ta, Hung Xuan ^a   Suoniemi, Matti ^a   Ekroos, Kim ^a   Hurme, Reini ^a   Lehtimäki, Terho ^b   Päivä, Hannu ^b   Kleber, Marcus E ^c,d   März, Winfried ^d,e,f   Prat, Annik ^g   Seidah, Nabil G ^g   Laaksonen, Reijo ^a,b  

^a Zora Biosciences   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c LURIC Study Nonprofit LLC   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Biomarker; Lipidomics; PCSK9

Indexed keywords

CHOLESTEROL ESTER; FATTY ACID; GALACTOSYLCERAMIDE; LACTOSYLCERAMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SPHINGANINE; SPHINGANINE 1 PHOSPHATE; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; STEARIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; LIPIDOMICS; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN DIET;

ANIMALS; BIOLOGICAL MARKERS; CHOLESTEROL ESTERS; CHOLESTEROL, LDL; GENOTYPE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUTATION; PHENOTYPE; PROPROTEIN CONVERTASES; PROSPECTIVE STUDIES; SERINE ENDOPEPTIDASES; SPHINGOLIPIDS;

EID: 84878107110     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.03.029     Document Type: Article

References (23)

1. Sirtori C.R., Mombelli G., Triolo M., Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Annu Mediaev 2011, 44(5):419-432.
2. Fernandez G., Spatz E.S., Jablecki C., Phillips P.S. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011, 78(6):393-403.
3. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34(2):154-156.
4. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100(3):928-933.
5. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. JLipid Res 2009, 50(Suppl.):S172-S177.
6. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37(2):161-165.
7. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. NEngl J Med 2006, 354(12):1264-1272.
8. Benn M., Nordestgaard B.G., Grande P., Schnohr P., Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. JAm Coll Cardiol 2010, 55(25):2833-2842.
9. Seidah N.G., Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. JMol Med 2007, 85(7):685-696.
10. Soutar A.K. Unexpected roles for PCSK9 in lipid metabolism. Curr Opin Lipidol 2011, 22(3):192-196.
11. Zaid A., Roubtsova A., Essalmani R., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008, 48(2):646-654.
12. Winkelmann B.R., Marz W., Boehm B.O., et al. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001, 2(1 Suppl. 1):S1-S73.
13. Ekroos K. Unraveling glycerophospholipidomes by lipidomics. Biomarker methods in drug discovery and development 2008, 369-384. Humana Press. F. Wang (Ed.).
14. Jung H.R., Sylvanne T., Koistinen K.M., Tarasov K., Kauhanen D., Ekroos K. High throughput quantitative molecular lipidomics. Biochim Biophys Acta 2011, 1811(11):925-934.
15. Liebisch G., Binder M., Schifferer R., Langmann T., Schulz B., Schmitz G. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim Biophys Acta 2006, 1761(1):121-128.
16. Stahlman M., Ejsing C.S., Tarasov K., Perman J., Boren J., Ekroos K. High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. JChromatogr B Analyt Technol Biomed Life Sci 2009, 877(26):2664-2672.
17. Ekroos K., Chernushevich I.V., Simons K., Shevchenko A. Quantitative profiling of phospholipids by multiple precursor ion scanning on a hybrid quadrupole time-of-flight mass spectrometer. Anal Chem 2002, 74(5):941-949.
18. Ekroos K., Ejsing C.S., Bahr U., Karas M., Simons K., Shevchenko A. Charting molecular composition of phosphatidylcholines by fatty acid scanning and ion trap MS3 fragmentation. JLipid Res 2003, 44(11):2181-2192.
19. Merrill A.H.J., Sullards M.C., Allegood J.C., Kelly S., Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005, 207-224.
20. Brito G.C., Andrews D.W. Removing bias against membrane proteins in interaction networks. BMC Syst Biol 2011, 5:169.
21. Raghow R., Yellaturu C., Deng X., Park E.A., Elam M.B. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab TEM 2008, 19(2):65-73.
22. Meikle P.J., Wong G., Tsorotes D., et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arteriosclerosis, Thromb Vasc Biol 2011, 31(11):2723-2732.
23. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007, 18(3):304-309.